Regeneron Pharmaceuticals Inc (REGN)

Lima
Currency in USD
1,062.75
0.00(0.00%)
Delayed Data
REGN Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
1,062.751,062.75
52 wk Range
1,009.101,093.35
Key Statistics
Edit
Prev. Close
1,009.1
Open
1,062.75
Day's Range
1,062.75-1,062.75
52 wk Range
1,009.1-1,093.35
Volume
-
Average Volume (3m)
8
1-Year Change
-
Book Value / Share
272.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
REGN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period
Show more

Regeneron Pharmaceuticals Inc Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Employees
15106
Market
Peru

Compare REGN to Peers and Sector

Metrics to compare
REGN
Peers
Sector
Relationship
P/E Ratio
17.2x−1.7x−0.6x
PEG Ratio
1.68−0.010.00
Price/Book
2.6x0.2x2.6x
Price / LTM Sales
5.4x0.8x3.1x
Upside (Analyst Target)
-202.8%48.2%
Fair Value Upside
Unlock19.0%8.0%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 40.9
Dividend Yield
-
Annualized payout
-
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 04, 2025
EPS / Forecast
12.07 / 11.27
Revenue / Forecast
3.79B / 3.76B
EPS Revisions
Last 90 days

People Also Watch

89.49
CCI
-0.02%
110.47
FTNT
+2.61%
745.52
KLAC
-0.29%
118.50
PLD
+0.98%
55.36
BMY
-2.62%

FAQ

What Is the Regeneron Pharma (REGN) Stock Price Today?

The Regeneron Pharma stock price today is 1,062.75

What Stock Exchange Does Regeneron Pharma Trade On?

Regeneron Pharma is listed and trades on the Lima stock exchange.

What Is the Stock Symbol for Regeneron Pharma?

The stock symbol for Regeneron Pharma is "REGN."

Does Regeneron Pharma Pay Dividends? What’s The Current Dividend Yield?

The Regeneron Pharmaceuticals Inc dividend yield is 0.08%.

What Is the Regeneron Pharma Market Cap?

As of today, Regeneron Pharma market cap is 75.04B.

What is Regeneron Pharma Earnings Per Share?

The Regeneron Pharma EPS is 40.90.

What Is the Next Regeneron Pharma Earnings Date?

Regeneron Pharma will release its next earnings report on May 01, 2025.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.